Application of combined omics platforms to accelerate biomedical discovery in diabesity
Kurland, Irwin J
Fischer, Steven M
Newgard, Christopher B
Ronnett, Gabriele V
Ryals, John A
Gross, Steven SNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationKurland, I. J., D. Accili, C. Burant, S. M. Fischer, B. B. Kahn, C. B. Newgard, S. Ramagiri, et al. 2013. “Application of combined omics platforms to accelerate biomedical discovery in diabesity.” Annals of the New York Academy of Sciences 1287 (1): 1-16. doi:10.1111/nyas.12116. http://dx.doi.org/10.1111/nyas.12116.
AbstractDiabesity has become a popular term to describe the specific form of diabetes that develops late in life and is associated with obesity. While there is a correlation between diabetes and obesity, the association is not universally predictive. Defining the metabolic characteristics of obesity that lead to diabetes, and how obese individuals who develop diabetes different from those who do not, are important goals. The use of large-scale omics analyses (e.g., metabolomic, proteomic, transcriptomic, and lipidomic) of diabetes and obesity may help to identify new targets to treat these conditions. This report discusses how various types of omics data can be integrated to shed light on the changes in metabolism that occur in obesity and diabetes.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11855879
- HMS Scholarly Articles